Karyopharm Therapeutics | KPTI - Ativos





Ativos Alterar Data
AbbVie USD 135.12B 1.35B 2026-06
Abbott USD 110.43B 23.72B 2026-03
Amgen USD 95.64B 3.14B 2026-06
AstraZeneca USD 115.83B 1.82B 2026-06
BioCryst Pharmaceuticals USD 557.85M 92.8M 2026-06
Bristol-Myers Squibb USD 87.63B 1.16B 2026-06
Eli Lilly USD 142.28B 25.71B 2026-06
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
GlaxoSmithKline GBP 61.74B 1.13B 2026-06
Incyte USD 7.87B 533.53M 2026-06
J&J USD 201.06B 167M 2026-06
Karyopharm Therapeutics USD 131.42M 23M 2026-03
MacroGenics USD 345.41M 127.54M 2026-06
Merck USD 129.8B 1.12B 2026-06
Nektar Therapeutics USD 763.27M 482.86M 2026-03
Novartis USD 122.03B 3.5B 2026-06
Novartis USD 118.53B 7.58B 2026-03
Pfizer USD 201.13B 6.49B 2026-06
Regeneron Pharmaceuticals USD 41.73B 861.8M 2026-06
Roche Holding CHF 98.2B 2.5B 2026-06
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Takeda JPY 15.66T 210.16B 2026-06
Tectonic Therapeutic USD 246.58M 14.46M 2026-03
TG Therapeutics USD 1.64B 110.79M 2026-06
Ultragenyx Pharmaceutical USD 1.26B 32M 2026-06
Xencor USD 724.96M 11.89M 2026-06